Checkpoint Trends Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Abha Kapoor

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.4yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Abha Kapoor

8.4yrs

Görev süresi

Ms. Abha Rajesh Kapoor serves as Whole-time Director at Checkpoint Trends Limited. He serves as Chief Financial Officer of Checkpoint Trends Limited (formerly known as Rubra Medicaments Limited) since June...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Abha Kapoor	CFO & Whole-time Director	8.4yrs	Veri yok	Veri yok
Sneha Thakur	Non Executive Independent Director	7.3yrs	Veri yok	Veri yok
Gopal Sahu	Non-Executive Independent Director	5.4yrs	Veri yok	Veri yok
Harish Surve	Non Executive Independent Director	3.6yrs	Veri yok	Veri yok

6.4yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 531099 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Checkpoint Trends Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Checkpoint Trends Limited Approves Appointment of Artee Sahu as Company Secretary and Compliance Officer

Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024

Checkpoint Trends Limited Announces Cessation of Sunil Khandalwal as Managing Director, with Effect from May 27, 2024

Insufficient new directors

Checkpoint Trends Limited Announces Resignation of Komal Behl, Company Secretary

Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023

Recent updates

New major risk - Revenue and earnings growth

Checkpoint Trends Limited to Report Q2, 2025 Results on Nov 11, 2024

Checkpoint Trends Limited to Report Q2, 2025 Results on Nov 11, 2024

Investor sentiment improves as stock rises 16%

Checkpoint Trends Limited Approves Appointment of Artee Sahu as Company Secretary and Compliance Officer

Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

First quarter 2025 earnings released

Checkpoint Trends Limited to Report Q1, 2025 Results on Aug 13, 2024

Investor sentiment deteriorates as stock falls 18%

Checkpoint Trends Limited Announces Cessation of Sunil Khandalwal as Managing Director, with Effect from May 27, 2024

Checkpoint Trends Limited to Report Q4, 2024 Results on May 25, 2024

Insufficient new directors

Investor sentiment improves as stock rises 15%

Third quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.004 in 3Q 2023)

Investor sentiment improves as stock rises 15%

Checkpoint Trends Limited to Report Q3, 2024 Results on Feb 07, 2024

Checkpoint Trends Limited Announces Resignation of Komal Behl, Company Secretary

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹0.47 (vs ₹0.02 in 2Q 2023)

Checkpoint Trends Limited to Report First Half, 2024 Results on Nov 07, 2023

Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released

Checkpoint Trends Limited to Report Q1, 2024 Results on Aug 11, 2023

Full year 2023 earnings released

Checkpoint Trends Limited to Report Q4, 2023 Results on May 26, 2023

Third quarter 2023 earnings released

Checkpoint Trends Limited to Report Q3, 2023 Results on Feb 13, 2023

Checkpoint Trends Limited Announces Company Secretary Changes

Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.03 in 2Q 2022)

Checkpoint Trends Limited to Report First Half, 2023 Results on Nov 10, 2022

Rubra Medicaments Limited, Annual General Meeting, Sep 30, 2022

Rubra Medicaments Limited to Report Q1, 2023 Results on Aug 11, 2022

Rubra Medicaments Limited to Report Fiscal Year 2022 Results on May 25, 2022

Rubra Medicaments Limited to Report Q3, 2022 Results on Feb 11, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹1.87

Third quarter 2021 earnings released

Rubra Medicaments Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹2.22

Market bids up stock over the past week

New 90-day low: ₹1.64

Rubra Medicaments Limited Announces Appointment of Ms. Ritu Chhatani as Company Secretary and Compliance Officer

Rubra Medicaments Limited Announces the Resignation of Manish Gandhi from the Post of Director

New 90-day high - ₹2.27

New 90-day low - ₹1.64

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi